



Using urinary MCP-1 and TWEAK to assess 
disease activity in a cohort of South African 
patients with lupus nephritis 
Submitted to the 
 
UNIVERSITY OF CAPE TOWN 
 
In fulfilment of the requirements for the degree 
 
MASTERS OF MEDICINE  
IN CHEMICAL PATHOLOGY 
 
Faculty of Health Sciences 



















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 











Dr Jody Alan Rusch 1,2 
Chemical Pathology Registrar 
Division of Chemical Pathology 
National Health Laboratory Service 
Groote Schuur Hospital  
jody.rusch@nhls.ac.za 
Tel: 021 404 4135 
PRINCIPAL INVESTIGATOR / SUPERVISOR 
Professor Ikechi Okpechi 3,4 
Professor of Nephrology 
Hypertension and Renal Unit 
Department of Medicine 
Groote Schuur Hospital 
ikechi.okpechi@uct.ac.za. 
Tel: 021 404 3321 
CO-SUPERVISOR 
Dr Fierdoz Omar 1,5 
Chemical Pathologist 
Honorary Senior Lecturer 
Division of Chemical Pathology 




Dr Walter Moloi3 
AFFILIATIONS: 
1. Division of Chemical Pathology, University of Cape Town and Groote Schuur
Hospital, Cape Town, South Africa
2. National Health Laboratory Services, Cape Town, South Africa
3. Division of Nephrology and Hypertension, University of Cape Town and Groote
Schuur Hospital, Cape Town, South Africa
4. Kidney and Hypertension Research Unit, University of Cape Town, South Africa
5. Lancet Laboratories, Cape Town, South Africa
Table of Contents 
DECLARATION .................................................................................................................................... 4 
ACKNOWLEDGEMENTS ...................................................................................................................... 5 
LIST OF TABLES AND FIGURE .............................................................................................................. 5 
GLOSSARY OF TERMS ......................................................................................................................... 6 
LIST OF ABBREVIATIONS .................................................................................................................... 7 
ABSTRACT ......................................................................................................................................... 9 
Background: ............................................................................................................................... 9 
Methods: ................................................................................................................................... 9 
Results: ...................................................................................................................................... 9 
Conclusion: ................................................................................................................................ 9 
Keywords: ................................................................................................................................ 10 
CHAPTER ONE ................................................................................................................................. 11 
CHAPTER 1: INTRODUCTION & LITERATURE REVIEW ...................................................................... 12 
1.1 Aim & Objectives ............................................................................................................ 12 
1.1.1 Aim ............................................................................................................................. 12 
1.1.2 Objectives .................................................................................................................. 12 
1.2 Introduction ................................................................................................................... 13 
1.2.1 Background ................................................................................................................ 13 
1.2.2 Monocyte chemoattractant protein-1 (MCP-1) .......................................................... 17 
1.2.3 Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) .............................. 19 
1.2.4 Hypothesis ................................................................................................................. 20 
1.2.5 Rationale for the Research ......................................................................................... 20 
1.2.6 Research Setting......................................................................................................... 21 
1.3 Ethical Considerations .................................................................................................... 22 
1.4 Author Guidelines for LUPUS.......................................................................................... 22 
1.5 References...................................................................................................................... 23 
CHAPTER TWO: PUBLICATION-READY MANUSCRIPT .............................. Error! Bookmark not defined. 
Appendices ..................................................................................................................................... 31 
Appendix 1: Ethics Approval Letters .............................................................................................. 9 
Appendix 2: Consent Forms......................................................................................................... 13 
Appendix 3: ALUGEN Registry Summary ..................................................................................... 16 
Appendix 4: Data Sheets ............................................................................................................. 17 
Appendix 5: SLEDAI-2K disease activity questionnaire ................................................................ 20 
Appendix 6: SLICC Scoring sheet.................................................................................................. 21 
Appendix 7: LUPUS - Journal Guidelines to Authors of Research Articles .................................... 22 
DECLARATION 
I, Jody Alan Rusch, hereby declare that the work on which this dissertation/thesis is based 
is my original work (except where acknowledgements indicate otherwise) and that neither 
the whole work nor any part of it has been, is being, or is to be submitted for another 
degree in this or any other university.  
I empower the university to reproduce, for the purpose of research, either the whole or 
any portion of the contents in any manner whatsoever. 
Signature: 
Date: 31st October 2019 
ACKNOWLEDGEMENTS  
 
§ Ikechi Okpechi for supervision, mentorship, support and encouragement  
§ Fierdoz Omar for supervision, mentorship, advice and analysis  
§ Mothusi Walter Moloi for collegiality, support and working hard on this project 
§ Judy King (deceased) for co-supervision of this project  
§ Joanne Pillay for advice, training and assistance in the laboratory 
§ Stephen Korsman and Anne Stewart for training and advice with the ELISA methodology, 
and use of equipment 
§ Duncan Freeman, Mauritz van den Worm and Chad Centner for statistical advice and help 
with analysis 
§ This work was funded by the National Research Fund (Funding number CPRR150703122950) 
§ This work was supported by the National Health Laboratory Services 
 
LIST OF TABLES AND FIGURE  
 
Table 1:   Baseline Characteristics of Study Participants 
Table 2:   Laboratory Results and Clinical Scores at Baseline, Six-Months and One-Year  
Figure 1:   Longitudinal analysis of MCP-1 and TWEAK Concentrations 
Figure 2 (a-d):    Diagnostic Accuracy in Identifying Disease Activity 
Supplementary Table 1:   Spearman’s Rank Correlations Between Biomarkers with rho (r) and p-
values (p) 
Supplementary Table 2:   Remission Status at Baseline and Follow-up 
Supplementary Figure 1:   Biomarker Concentrations as a Function of Remission Status 
Table 3:   Remission Status 
 
GLOSSARY OF TERMS 
 
ALUGEN Registry  
o The African Lupus Genetics Network Registry is a multi-centred framework seeking to 
prospectively assess outcomes in SLE patients in Africa 
Chemokine 
o Chemokines are a family of chemoattractant cytokines (small proteins secreted by cells that 
influence the immune system) which play a vital role in cell migration through blood vessels 
from blood into tissue and vice versa, and in the induction of cell movement in response to a 
chemical (chemokine) gradient by a process known as chemotaxis 
Cytokine 
o A group of small proteins that are important in cell signalling. They are released by cells and 
affect the behaviour of other cells 
ELISA 
o The enzyme-linked immunosorbent assay is a common laboratory technique which is used 
to measure the concentration of an analyte (usually antibodies or antigens) in solution 
Lupus Nephritis  (LN) 
o A common and serious complication in patients with SLE, whereby there is inflammation of 
the kidneys 
Monocyte Chemoattractant protein-1 (MCP-1) 
o A leucocyte chemotactic factor involved in mediating renal inflammation and injury in LN 
Systemic Lupus Erythematosus (SLE)  
o A multi-systemic autoimmune disease 
SLEDAI-2K Score   
O A scoring system to assess Systemic Lupus Erythematosus disease activity 
Renal SLEDAI-2K Score   
o A scoring system to assess kidney disease activity in patients with LN and consists of four 
parameters (haematuria, pyuria, proteinuria and urinary casts) 
SLICC/ACR Damage Index  
o A scoring system used to assess disease activity and damage in SLE patients.  
Tumour Necrosis Factor-like Weak Inducer of Apoptosis (TWEAK) 
o A cytokine and member of the tumour necrosis factor superfamily, TWEAK is involved in pro-
inflammatory responses. 
LIST OF ABBREVIATIONS  
 
ANA     Anti-Nuclear Antibody 
Anti-dsDNA    Anti-Double Stranded Deoxyribonucleic Acid  
Anti-Sm     Anti-Smith 
C3      Complement Component 3 
C4      Complement Component 4 
CC    Chemotactic cytokine 
CCR2    Chemokine Receptor 2 
CKD    Chronic kidney disease 
CKD-EPI   Chronic Kidney Disease Epidemiology Collaboration 
eGFR      Estimated Glomerular Filtration Rate 
ELISA      Enzyme-Linked Immunosorbent Assay 
ESRD      End-Stage Renal Disease 
FBC      Full Blood Count 
Fn14      Fibroblast Growth Factor Inducible 14 
GSH      Groote Schuur Hospital 
HIVAN     Human Immunodeficiency Virus Associated Nephropathy  
HREC      Human Research Ethics Committee 
ICAM-1     Intercellular Adhesion Molecule-1 
IP-10      Interferon gamma induced Protein-10 
ISN/RPS     International Society of Nephrology/ Renal Pathology Society 
LN      Lupus Nephritis 
MCP-1     Monocyte Chemoattractant Protein-1 
MCP-1/Cr   Urinary MCP-1 normalised to urinary creatinine 
MDRD     Modification of Diet in Renal Disease 
MIP-1á     Macrophage Inflammatory Protein-1á 
MMP-1     Matrix Metalloproteinase-1 
MMP-9     Matrix Metalloproteinase-9 
RANTES     Regulated in Activation, Normal T Expressed and Secreted 
SLE      Systemic Lupus Erythematosus 
SLEDAI-2K Score    SLE Disease Activity Index 2000 
SLICC/ACR Damage Index   Systemic Lupus Collaborating Clinics/American College of 
Rheumatology Damage Index 
TNF Tumour Necrosis Factor 
TWEAK     Tumour Necrosis Factor-like Weak Inducer of Apoptosis 
TWEAK/Cr   Urinary TWEAK normalised to urinary creatinine 
uMCP-1   Urinary MCP-1 
UPCR      Urine Protein to Creatinine Ratio 
uTWEAK   Urinary TWEAK 





















Renal involvement is common in systemic lupus erythematosus (SLE) and can lead to chronic kidney 
disease (CKD). Diagnosis of lupus nephritis (LN) is dependent on renal biopsy. Due to its invasiveness, 
repeat renal biopsy for monitoring disease activity is not recommended, thus creating a need for non-
invasive and accurate biomarkers. Monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis 
factor-like weak inducer of apoptosis (TWEAK) have been implicated in the pathogenesis of LN and 
are thus potential biomarkers for disease activity monitoring. 
Methods:  
In this study urinary MCP-1 (uMCP-1) and TWEAK (uTWEAK), together with standard markers of 
disease activity, were analysed in a cohort of 50 biopsy-proven LN patients at baseline, after six-
months of induction therapy, and at one-year. 
Results: 
Throughout the study there was correlation between uMCP-1 and uTWEAK (r=0.52, p<0.001). Both 
biomarkers also correlated with standard of care tests and clinical scores. The median [interquartile 
range] of uMCP-1 and uTWEAK were significantly increased in the active group when compared to the 
quiescent group (1440 [683–2729] vs 256 [175–477] pg/mL, p<0.0001, and 209 [117–312] vs 74 [11–
173] pg/mL, p=0.0008, respectively). After completion of induction therapy in the active group, there 
was no significant difference in biomarker results between the groups. The sensitivity and specificity 
for indicating disease activity was 95% and 73% for uMCP-1 (area under curve [AUC]=0.875), and 60% 
and 90% for uTWEAK (AUC=0.783), respectively. 
Conclusion: 
uMCP-1 and uTWEAK reflect LN disease activity, and correlate with standard of care biomarkers in a 
South African cohort. Further studies are needed to assess additional clinical benefit. 
Keywords: 
MCP-1, monocyte chemoattractant protein-1; TWEAK, tumour necrosis factor-like weak inducer of 
apoptosis; urinary biomarkers; lupus nephritis; systemic lupus erythematosus; disease activity; renal 
biopsy 






















































CHAPTER 1: INTRODUCTION & LITERATURE REVIEW  
 




The aim of this study was to prospectively assess the diagnostic performance and value of the urinary 
biomarkers MCP-1 and TWEAK as predictors of disease activity status in LN 
1.1.2 Objectives 
 
The objectives of this study were as follows: 
1. To determine the participants disease activity level at baseline using currently available 
modalities including:  
a. Biochemical parameters: urinalysis, serum creatinine, complements (C3 and C4) and 
autoantibodies (anti-nuclear antibody [ANA], anti-double stranded deoxyribonucleic 
acid [anti-dsDNA] and anti-Smith [anti-Sm]). 
b. Disease activity scores: Systemic Lupus Erythematosus Disease Activity Index 
2000 (SLEDAI-2K), renal SLEDAI (rSLEDAI) and Systemic Lupus Collaborating 
Clinics/American College of Rheumatology Damage Index (SLICC) scores   
c. Renal biopsy – only the active group had a new biopsy 
2. To analyse the uMCP-1 and uTWEAK levels of the participants using ELISA methodology 
3. To determine the utility of uMCP-1 and uTWEAK in the assessment of disease activity 
status in LN 
 
 
1.2 Introduction  
 
1.2.1  Background 
 
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease characterised by complex 
protean clinical manifestations involving multiple organ systems. The patients’ presentation and 
course of the disease are highly variable, relapsing and remitting, and ranging from indolent to 
fulminant. Their prognosis is also variable and depends upon the organ systems involved. Although 
considerable advances have been made in understanding the complex clinical features and 
unpredictable progression of SLE, the pathogenesis remains unclear. The features of SLE are related 
to immune dysregulation, including autoantibody production, activation of complement pathways, 
and immune complex deposition in target tissues(1).  Recent investigations have addressed the roles 
of chemokines and cytokines in the regulation of lupus disease activity and specific organ 
involvement, including the kidneys(2,3). 
Renal involvement is common in SLE, with approximately 60% of patients developing clinically 
significant renal disease(4). Most renal abnormalities emerge soon after diagnosis, commonly within 
the first six to 36 months(4).  A wide range of abnormalities have been described in lupus nephritis 
(LN), from asymptomatic proteinuria or microscopic haematuria with normal renal function, to 
severe nephrotic syndrome or acute renal failure(5). Some patients with LN develop 
hypertension(6). Approximately 10–15% of nephritis patients progress to end-stage renal disease 
(ESRD) requiring haemodialysis(4).  An abnormal urinalysis (protein or blood) or an elevation in 
serum creatinine should alert the clinician to the possible presence of LN. Unfortunately, significant 
kidney damage usually occurs before renal impairment is detected by laboratory tests.  
LN is an immune complex glomerulonephritis involving multiple factors which include genetic 
predisposition, epigenetic modification and environmental components. The pathogenesis of LN is 
complex involving both innate and adaptive immunity in a loss of self-tolerance. Deposition and/or 
in situ production of autoantibodies (e.g. anti-dsDNA) in the glomerulus, activation of complements 
(e.g. C3 and C4), T cells and macrophages, production of pro-inflammatory cytokines and 
chemokines, aberrant micro-RNA expression, cell proliferation and the production of extracellular 
matrix proteins, are then linked through multiple mechanisms to cause tubular damage, tubulo-
interstitial inflammation and fibrosis(7). In addition, genome-wide association studies have 
highlighted the role of genetic variants predisposing patients to renal damage in SLE(8).   
The prevalence and severity of SLE appears to vary among geographical regions and ethnic groups. 
The variation in prevalence estimates of LN between studies may be due to racial differences in 
disease prevalence, risk of nephropathy, and varying definitions of criteria for diagnosis of the 
disease(9–14). The prevalence of LN is higher in blacks (34 – 51%), Hispanics (31 – 43%), and Asians 
(33 – 55%), than it is in whites (14 – 23%)(9–14). Blacks and Hispanics also tend to present with more 
severe underlying histopathology, higher serum creatinine concentrations, and more severe 
proteinuria than whites(15). In addition, blacks, Hispanics and those living in poverty have a worse 
prognosis than whites and those with a higher socioeconomic status(16). There is growing evidence 
that in Africa SLE is prevalent and runs a severe course(17). In Cape Town, South Africa, LN is a 
common cause of chronic kidney disease (CKD) and ESRD requiring dialysis(18). Up to 25% of 
patients develop ESRD within 10 years of diagnosis of LN, despite recent advances in 
management(18). Earlier diagnosis, and hence treatment, has a beneficial effect on the prognosis of 
LN, and it has been shown that late diagnosis is correlated with a higher frequency of renal 
insufficiency and increased incidence of ESRD(19,20).  
The goals of therapy in LN include maintaining the lowest possible disease activity, preventing end-
organ damage, minimising drug toxicity, improving quality of life, educating patients (e.g. regarding 
their role in disease management) and long-term survival. Immunosuppressive agents are important 
in the treatment of many inflammatory, allergic, immunologic and malignant disorders. 
Unfortunately, toxicity is one of the commonest causes of iatrogenic illness associated with chronic 
inflammatory diseases. The side effects profile associated with immunosuppressive therapy is well 
documented. These side effects include sepsis, diabetes mellitus, hypothalamic-pituitary-adrenal 
insufficiency, avascular necrosis of the hip, cushingoid features, and other systemic (e.g. 
dermatological, musculoskeletal, renal, eye, cardiovascular, gastrointestinal and neuropsychiatric) 
manifestations(21–24). LN is a serious disease whose prognosis can usually be improved 
dramatically with immunosuppressive treatment. Current treatment regimens combine 
corticosteroids with cyclophosphamide, azathioprine, cyclosporin and mycophenolate mofetil. 
Treatment of LN is prolonged, complex and potentially toxic. In local studies, sepsis was a major 
complication related to immunosuppressive treatment in LN and often resulted in prolonged 
hospitalization; sepsis was also a frequent cause of death in these patients (25,26). Determining the 
appropriate therapeutic regimen for LN requires an accurate assessment of both disease activity and 
severity, as active disease and quiescent disease can alternate and fluctuate and therefore require 
treatment modifications(27–31).  
Disease activity can be defined as reversible manifestations of an underlying inflammatory process 
at a point in time in terms of magnitude and intensity(32). Disease severity can be defined as the 
type and level of organ dysfunction and its consequences(32). The degree of irreversible organ 
dysfunction is referred to as damage(32). In LN there are generally three patterns of disease activity 
to consider namely intermittent disease flares, chronically active disease, and quiescent disease. An 
ongoing challenge in the management of LN is how to continuously and non-invasively evaluate 
disease activity and hence identify a renal flare. This would allow for the timeous and appropriate 
commencement of highly potent immunosuppression. At present, LN disease activity and severity 
are assessed using a combination of clinical symptoms, physical examination and biochemical 
parameters such as urinalysis, serum creatinine, complement and autoantibodies. However, the 
correlation between these biomarkers and LN is imperfect, and their utility in reflecting disease 
activity and in predicting outcome remains controversial(33). They remain unsatisfactory because 
they lack sensitivity and/or specificity for differentiating renal activity and damage in LN(34). Table 1 
demonstrates the diagnostic performance of some of these biomarkers(35).  
 
Table 1: Sensitivity & specificity ranges of biomarkers for active lupus nephritis 
TEST SENSITIVITY SPECIFICITY 
Anti-dsDNA 53 - 100% 50 - 69% 
C3 56 - 79% 51 - 64% 
C4 53 - 74% 64 - 65% 
Anti-C1q 53 - 81% 64 - 71% 
 
* Reproduced from Reyes-Thomas J, Blanco I, Putterman C. Urinary Biomarkers in Lupus Nephritis. 
2011(35) 
 
The histological analysis of kidney tissue is the gold standard for diagnosing and classifying LN and 
can be used in the assessment of renal disease activity and damage. However, the invasiveness and 
risk of the procedure, as well as access to this modality, dramatically decrease its pragmatic clinical 
use(36). Complications include death in 0.02% - 0.1% of patients(36). Serial renal biopsies are 
therefore not usually performed or recommended. Therefore, novel biomarkers that are able to 
discriminate disease activity and severity, predict flares, and monitor treatment response and 
disease progression are clearly required. Non-invasive, easy to obtain, and accurate biomarkers that 
can be followed-up serially would be of great value in the management of LN patients.  
A potential biomarker in LN should be biologically plausible and relevantly involved in the 
pathogenesis, although it may not be specific for it(37). Candidate biomarkers should optimally 
predict the renal histology, while they may also predict long term outcomes such as deterioration in 
renal function or renal death requiring dialysis or transplantation. Biomarkers should perform better 
than the standard-of-care tests, but also show significant correlation with them(38). They should be 
cost-effective, reasonably simple to measure routinely and easily interpretable. In addition, they 
should be sensitive to change and thus appropriate for the serial monitoring of disease activity, 
treatment response, remission and relapse(37). Furthermore, they should optimally have the ability 
to predict changes before alterations in standard clinical parameters become apparent so that early 
treatment, or preventative strategies, can be implemented promptly(34). Finding biomarkers that 
fulfill these criteria will help in disease activity evaluation, identify patients at risk for kidney 
damage, and facilitate early diagnosis and intervention to improve favourable outcomes. 
Urinary biomarkers are easily obtained by non-invasive means and reflect current renal status, as 
they specifically represent local inflammatory activity(39). In health, 70% of the protein content 
within the urine originates in the urinary tract, whereas only 30% originates from filtered 
plasma(40). Instrumental in the pathogenesis of LN, cytokines and chemokines (secreted locally in 
the kidneys) are expelled in urine samples(39,41). Furthermore, it has been shown that the excretion 
of these biomarkers in the urine is a good indicator of their local production and secretion(35,42,43). 
Urinary biomarkers such as monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis 
factor-like weak inducer of apoptosis (TWEAK) may therefore more accurately reflect renal 
inflammatory disease activity in LN than serum markers. 
 
1.2.2  Monocyte chemoattractant protein-1 (MCP-1)  
 
Monocyte chemoattractant protein-1 is a low molecular weight member of the CC chemokine 
subfamily(44). Chemokines include proteins that play central roles in many biological and pathological 
processes. Chemokines were initially identified as regulators of leukocyte trafficking, with subsequent 
studies demonstrating their involvement in other aspects of the inflammatory process, such as tissue 
remodeling, angiogenesis and fibrosis(45–48). Chemokines have multiple actions and functions, and 
thus play a major role in various auto-immune diseases, allergic disorders and transplant rejections, 
and in vascular, neoplastic and infectious conditions.  Changes in chemokine expression or function 
lead to the persistence of an inflammatory reaction beyond its original purpose thereby creating a key 
pathogenic event for the establishment of chronic inflammation(49).  
The role of MCP-1 as a potent monocyte attractant linked to innate immunity is well documented(50). 
MCP-1 exerts its effects through binding to G-protein-coupled receptors, namely CCR2, on the surface 
of leukocytes targeted for activation and migration(49). MCP-1 attracts T cells, natural killer cells, and 
basophils in acute inflammatory conditions, and acts as an important mediator in chronic 
inflammation(44).  
SLE patients have higher serum MCP-1 levels than healthy controls, even in the absence of 
symptoms(51). MCP-1 has been shown to play a major role in inflammatory processes in renal disease 
linked to SLE and have been reported to increase with the progression of disease activity in patients 
with LN(52–57).  In animal models, MCP-1 antagonism or gene therapy ameliorated these 
inflammatory effects, and MCP-1 knockout mice were less prone to LN(58–60). Being a small protein, 
MCP-1 is easily filtered by the glomerulus from the plasma into the urine. MCP-1 is also produced 
locally in the kidneys by renal mesangial cells, endothelial cells, tubular epithelial cells, and smooth 
muscle cells(49). In humans, when compared to a wide range of cytokines, urinary MCP-1 (uMCP-1) 
performed better as a marker of disease activity in SLE, was reported to correlate with LN disease 
activity, and seemed to have the potential to predict renal flares(38,43,49,61). In a 2012 study by 
Barbado et al, uMCP-1, when compared with 26 other cytokines, chemokines and cellular growth 
factors, was shown to be the best biomarker for detection of disease activity in SLE(49). In addition, 
uMCP-1 levels have been shown to be significantly correlated with both LN class and severity of LN 
flare, and to decline in response to treatment(38,62). Thus uMCP-1 is a good candidate as a non-
invasive biomarker for assessing LN disease activity.  
 
1.2.3 Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) 
 
The cytokine TWEAK was first discovered in 1997 and assigned to the tumour necrosis factor (TNF) 
superfamily, the members of which play pivotal roles in regulating the immune system(63). TWEAK 
was named for its relation to TNF, proinflammatory effects and weak ability to promote cell death. 
The human TWEAK gene encodes a 249 amino acid type II transmembrane glycoprotein which is 
proteolytically cleaved into a soluble form that circulates as a trimer believed to be the primary 
mediator of its effects(64). The major source of circulating TWEAK is activated monocytes and 
macrophages although it is expressed in many tissues. In the kidneys, both resident kidney cells and 
infiltrating leucocytes express TWEAK(65). Currently the only known TWEAK receptor is fibroblast 
growth factor inducible 14 (Fn14)(64).  
Evidence has developed supporting a role for TWEAK activation of intrinsic renal cell Fn14 receptors 
in the pathogenesis of various kidney diseases, including LN(65). In renal cells TWEAK mediates the 
following effects: proliferation, differentiation, migration, enhancement of cell survival, tissue 
regeneration, modulation of cell death and apoptosis, upregulation of proinflammatory mediators 
(multiple chemokines, cytokines and adhesion molecules) and neoangiogenesis(63–68). Human 
mesangial cells, podocytes and tubular cells have all been found to express Fn14 and renal biopsies of 
LN patients have demonstrated strong glomerular and tubulointerstitial staining for Fn14(69). TWEAK 
induces the expression of multiple inflammatory mediators, including RANTES, MCP-1, IP-10, MIP-1á, 
ICAM-1, VCAM-1, MMP-1, and MMP-9(68). In addition, recent studies have shown that TWEAK 
significantly stimulated proliferation of mesangial cells and podocytes(64).  
Based on these considerations urinary TWEAK (uTWEAK) may be a useful biomarker in patients with 
LN. TWEAK may be even more revealing than individual chemokines, since TWEAK is proximal in the 
inflammatory cascade and induces several nephritis-related mediators(35). TWEAK effects 
downstream expression of inflammatory messengers, including MCP-1, in human mesangial cells, 
podocytes, and tubular cells(68,70).  In early multicentre studies of SLE patients by Schwartz and 
colleagues, uTWEAK was found to be higher in those with LN, than in control groups (overall 
significance p=0.039; SLE non-LN p=0.005; healthy control p=0.003; rheumatoid arthritis p=0.013). 
Additionally, they found uTWEAK levels would peak during a LN flare, and decrease after the flare, 
indicating its potential usefulness as a marker of LN disease activity(39,62). More recently, studies in 
Egypt(71–74), China(75,76), Colombia(77), Korea(78), Mexico(79) and Thailand(80) have confirmed 
uTWEAK’s potential as a biomarker in diverse populations of LN.  
 
1.2.4 Hypothesis  
 
Urinary levels of MCP-1 and TWEAK will reflect the level of renal disease activity in patients with LN. 
The levels of these biomarkers will be significantly increased in patients with active LN when compared 
with patients with quiescent LN. The levels of these biomarkers will decrease with response to 
treatment. The levels of these biomarkers will correlate with other standard tests of disease activity 
status in LN. 
 
1.2.5 Rationale for the Research  
 
Lupus nephritis is regarded as the most serious common complication of SLE. The relapsing and 
remitting course of LN requires close surveillance of disease activity status and appropriate treatment 
modifications throughout patients' lives. Judicious use of immunosuppression in patients with active 
LN is required as the treatment may have serious complications. Although renal biopsy remains the 
gold standard to assess disease activity status, repeat biopsies are not recommended, rendering the 
procedure impractical as a clinical monitoring tool. Current modalities for assessing disease activity 
status include clinical scores and laboratory tests such as urinalysis, serum creatinine, complement 
and autoantibodies. The diagnostic performance of these modalities remains unsatisfactory. A non-
invasive and reliable biomarker that reflects LN disease activity status is therefore highly desirable. 
Preliminary studies have shown that uMCP-1 and uTWEAK correlate with disease activity, and may 
predict renal flares, response to treatment and histology. These biomarkers may also enhance patient 
management, thereby decreasing morbidity and mortality.  
Few studies have assessed uMCP-1 and uTWEAK in the same cohort of patients, and to the best of our 
knowledge no studies have been performed in a South African cohort of patients. Previous studies 
were limited in length of follow-up to less than six-months. Furthermore, previous studies reported 
either absolute concentrations of the biomarkers or concentrations corrected for urinary creatinine, 
not both. Moreover, some studies did not demonstrate disease activity in the active group with the 
gold-standard renal biopsy.    
In this study, uMCP-1 and uTWEAK were assessed in a cohort of South African patients with active and 
quiescent LN at baseline, and longitudinally at six-months and one-year. We reported both absolute 
concentrations of the biomarkers and values corrected for urinary creatinine, and compared their 
usefulness. Lastly, the active group in our study had a recent renal biopsy demonstrating disease 
activity.   
1.2.6 Research Setting  
 
For this study the cohort of patients were recruited from the Department of Medicine, Division of 
Nephrology and Hypertension, Groote Schuur Hospital (GSH), Cape Town, South Africa, over a two-
year period. GSH is a large, government-funded, teaching hospital. The hospital serves the central 
health district of the Cape Town Metro region, with a diverse socioeconomic and cultural population.  
In this prospective observational study, the patients were each followed up over a one-year period.  
The patients were newly diagnosed with LN (biopsy proven) or known LN patients with a previous 
renal biopsy.  Two groups of patients were identified depending on their current disease activity 
status:  
1. Active disease group 
2. Quiescent disease group   
 
1.3 Ethical Considerations 
 
Ethical approval for this study was granted by the University of Cape Town Human Research 
Ethics Committee (HREC), as a sub-study of the ongoing ALUGEN Registry(81) of patients with 
SLE in Cape Town.  Please see Appendix 1 for the relevant documentation pertaining to the 
study’s formal approval (HREC/REF:402/2014 and HREC/REF:856/2016)) and the annual 
progress report and renewal forms (FHS016).   
Signed informed consent was obtained from all patients enrolling in the study.  Please see 
Appendix 2 for a copy of the patient consent form. Strict adherence to patient confidentiality 
and anonymity was maintained. Patient information was recorded in a database for sole use 
by the researchers involved in the study. See Appendix 3 for the ALUGEN Registry summary 
and Appendix 4 for the Data Sheets. Patients names were encoded and did not appear on the 
sample tubes used during the study. Appendices 5 and 6 detail the scoring systems using 
SLEDAI-2K and SLICC, respectively.   
Important ethical issues that were considered in the development of this study included the 
collection of patient samples (blood and urine), access to participant information and medical 
records, and the confidentiality thereof. 
 
1.4 Author Guidelines for LUPUS 
Author guidelines for article submission to Lupus (in their exact words) are attached in 
Appendix 7. 
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Abstract  
Background:  Renal involvement is common in systemic lupus erythematosus (SLE) and can 
lead to chronic kidney disease. Diagnosis of lupus nephritis (LN) is dependent on renal biopsy. 
Due to its invasiveness, repeat renal biopsy for monitoring disease activity is not 
recommended, thus creating a need for non-invasive and accurate biomarkers. Monocyte 
chemoattractant protein-1 (MCP-1) and tumour necrosis factor-like weak inducer of 
apoptosis (TWEAK) have been implicated in the pathogenesis of LN and are thus potential 
biomarkers for disease activity monitoring.  
Methods:  In this study urinary MCP-1 (uMCP-1) and TWEAK (uTWEAK), together with 
standard markers of disease activity, were analysed in a cohort of 50 biopsy-proven LN 
patients at baseline, after six-months of induction therapy, and at one-year.  
Results:  At baseline, there was correlation between uMCP-1 and uTWEAK. Both biomarkers 
also correlated with standard of care tests, and clinical scores. The median [interquartile 
range] of uMCP-1 and uTWEAK were significantly increased in the active group when 
compared to the quiescent group (1440 [683–2729] vs 256 [175–477] pg/mL, p<0.0001, and 
209 [117–312] vs 74 [11–173] pg/mL, p=0.0008, respectively). After completion of induction 
therapy in the active group, there was no significant difference in biomarker results between 
the groups. The sensitivity and specificity for indicating disease activity was 95% and 73% for 
uMCP-1, and 60% and 90% for uTWEAK, respectively,.  
Conclusions:  uMCP-1 and uTWEAK reflect LN disease activity, and correlate with standard of 
care biomarkers in a South African cohort, however, further studies are needed to assess 
additional clinical benefit. 
Introduction 
Background and Rationale 
An unmet need in the management of lupus nephritis (LN) is how to regularly and non-
invasively evaluate disease activity and severity, as this would allow for the judicious 
utilisation of appropriate therapeutic regimens. Although renal biopsy remains the gold 
standard, invasiveness, risk and access to the procedure dramatically decrease its pragmatic 
clinical use.  At present, disease activity and severity are assessed using a combination of 
clinical and biochemical parameters. Standard of care biomarkers include proteinuria and 
urinalysis, serum creatinine, complement (C3 and C4) and various autoantibodies. However, 
the correlation between these biomarkers and LN is imperfect, restricted by low sensitivities 
or specificities(1). Their utility in accurately reflecting renal disease activity and in predicting 
outcomes remains controversial(2).  
Within the kidney, locally secreted chemokines such as monocyte chemoattractant protein-1 
(MCP-1) and cytokines such as tumour necrosis factor-like weak inducer of apoptosis (TWEAK) 
are instrumental in the pathogenesis of LN(3–5). The role of MCP-1 and its receptor 
chemokine receptor 2 (CCR2) as a potent monocyte attractant linked to innate immunity is 
well documented(6). Briefly, MCP-1 attracts T cells, natural killer cells, and basophils in acute 
inflammatory conditions, and acts as an important mediator in chronic inflammation(7). 
Furthermore, MCP-1 is involved in other aspects of the inflammatory process, such as fibrosis, 
tissue remodelling and angiogenesis(7).  
The cytokine TWEAK is expressed by both infiltrating leucocytes (monocytes and 
macrophages) and resident kidney cells(1). Initially membrane-bound, TWEAK is 
proteolytically processed into a soluble form that circulates as a trimer believed to be the 
primary mediator of its biological effects via its receptor fibroblast growth factor-inducible 14 
(Fn14) which is expressed by various cells in the kidney (8,9). Proximal in this inflammatory 
pathway, TWEAK/Fn14 stimulates mesangial cells to secrete pro-inflammatory cytokines like 
MCP-1, RANTES, IP-10, CXCL-1 and CVCAM-1, which lead to the recruitment of activated T 
cells and mediates other biological processes such as cell growth, tissue remodelling, 
angiogenesis, fibrosis and apoptosis(8).  
Excretion of MCP-1 and TWEAK in the urine has been shown to be a good indicator of their 
local production and secretion(1,4). Therefore, these two novel urinary biomarkers may 
accurately reflect renal inflammatory disease activity in LN. Few studies have assessed them 
in combination and, to the best of our knowledge, no studies have been performed in a South 
African cohort of patients. In this study, the urinary levels of MCP-1 (uMCP-1) and TWEAK 
(uTWEAK) were assessed in patients with active and quiescent LN at baseline and 
longitudinally at six-months and one-year.  
 
Materials and Methods 
Study Design and Population 
In this prospective observational study, a cohort of fifty patients with biopsy-proven LN was 
recruited from the Nephrology Clinic at Groote Schuur Hospital in Cape Town during the 
period August 2016 to December 2017. This consisted of a clinically stable group with 
quiescent LN (sample number [n] =30) and a group with clinically active LN (n=20). The 
quiescent group were patients known to have LN, confirmed in the past with renal biopsy, 
and followed up at the nephrology clinic. Inactive disease status was confirmed clinically by 
history, physical examination, disease activity scores, and biochemical assessments (urine and 
serum). The active group were newly diagnosed patients with LN (confirmed on renal biopsy) 
or known patients with current disease relapse with repeat biopsy confirming active disease. 
Participants who consented to take part in this study were 18 years or older, and diagnosed 
with SLE according to ACR criteria(10). Patients not included were those with co-morbid HIV 
infection, SLE patients with renal disease but with no renal biopsy, those with inadequate 
renal biopsy, or if the biopsy indicated alternative or dual renal pathologies. Approval for this 
study was obtained from the University of Cape Town Human Research Ethics Committee. 
Study Data Collection 
At baseline, relevant demographic, clinical and biochemical data were collected. SLE Disease 
Activity Index 2000 (SLEDAI-2K) and renal SLEDAI (rSLEDAI) scores were also completed to 
evaluate general and renal disease activity, respectively(11). Additionally, SLICC (Systemic 
Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index) 
scores were obtained(12).  
Plasma and serum samples were referred to the hospital’s accredited central laboratory 
where biochemical parameters were analysed using standard methods. This included 
creatinine and complement (C3 and C4) performed on the Roche Cobas 6000, full blood count 
on the Sysmex XN-9000, and autoantibodies anti-double-stranded DNA (anti-dsDNA), anti-
Smith (anti-Sm) and anti-nuclear antibodies (ANA) on the Thermo Scientific EliA Phadia 250. 
The estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI 
equation(13). Aliquots of urine were used to qualitatively and quantitatively assess for blood 
and protein. Four further aliquots were centrifuged and stored at -80 degrees Celsius for the 
batched analysis of uMCP-1 and uTWEAK by ELISA methodology according to previously 
described methods(14,15) and the relevant package inserts. Follow-up tests were performed 
at six-months and one-year. 
Measurement of uMCP-1 and uTWEAK  
uMCP-1 was measured using the Human MCP-1 Quantikine ELISA Kit by R&D Systems. This 
assay has a measuring range of 31.3 to 2000 picograms per millilitre (pg/mL) and performs 
with an inter-assay precision of 5.9%. uTWEAK was measured using the TWEAK Human 
Instant ELISA Kit by eBioscience (Thermo Fisher Scientific). This assay has a measuring range 
of 15.6 to 1000 pg/mL and performs with an inter-assay precision of 7.9%. Samples with 
analyte concentrations above the measuring range were repeated in dilution. Both uMCP-1 
and uTWEAK results were also mathematically normalised to the urine creatinine (uCr) 
concentration. These results were denoted as MCP-1/Cr and TWEAK/Cr and expressed as 
picograms per milligram of creatinine (pg/mg Cr).  
Renal Biopsy 
All patients in the active group underwent biopsy at enrolment into the study and their 
histology results were interpreted by anatomical pathologists at our centre using the 
International Society of Nephrology/ Renal Pathology Society Classification(16).  
Definition of Remission 
Remission status was described as complete, partial or no remission. Complete remission (CR) 
in LN was defined as return of serum creatinine to previous baseline, plus a decline in the 
UPCR to <0.050 g/mmol. Partial remission (PR) was defined as stabilisation (±25%), or 
improvement of serum creatinine, but not to normal, plus a ≥50% decrease in UPCR. 
Alternatively, if there was nephrotic-range proteinuria then improvement required a ≥50% 
reduction in UPCR, and a UPCR <0.300 g/mmol. Patients not meeting the above criteria were 
considered to have no remission (NR)(17). 
Statistical Analysis 
Statistical analysis was performed using Stata (StataCorp LLC). The data were summarised as 
means and standard deviations (mean [±SD]), or medians and interquartile ranges (median 
[p25–p75]), depending on whether the data were normally distributed or non-parametric, 
respectively. Categorical variables were summarised with frequencies and percentages. The 
data were tested for normality using the Shapiro-Wilk test, and most data found to be 
distributed non-parametrically. Groups were compared using Wilcoxon rank-sum tests for 
non-parametric data, or if normally distributed, the student t-test. Variables were assessed 
using Spearman correlation or linear regression models. Receiver operating characteristic 
(ROC) curves were generated for diagnostic test evaluation to assess the sensitivity and 
specificity pair corresponding to a particular decision threshold for disease activity and to 
measure how well the biomarkers performed in distinguishing between active and quiescent 
patients by area under the curve (AUC). A p-value <0.05 was deemed statistically significant.  
Results 
Baseline Characteristics of the Study Population 
The baseline characteristics of the study population are presented in Table 1. Overall, there 
was a preponderance of females (76%) of mixed ancestry (64%) and the median age of all 
participants was 36 years. The active group (n=20) was both significantly younger and had a 
shorter duration of SLE. The histological diagnoses of the active group were class II (n=2), class 
III (n=3), class IV (n=9), class V (n=4), class III+IV (n=1) and class IV+V (n=1). Most active 
participants therefore had proliferative LN (defined as classes III and IV, with or without class 
V) (n=14, 70%). Half of the patients demonstrated the presence of interstitial fibrosis in their 
biopsy report.  
Baseline and Follow-up Clinical and Laboratory Findings  
The patients’ LN disease scores (SLEDAI-2K, rSLEDAI and SLICC) are presented in Table 2. At 
baseline, the active group SLEDAI-2K (p<0.0001), rSLEDAI (p<0.0001) and SLICC (p<0.0001) 
scores were higher than the quiescent group. At six-months, SLEDAI-2K scores remained 
increased in the active group (p=0.001), whereas rSLEDAI (p=0.41) and SLICC (p=0.07) scores 
were not different between the two groups. At one-year, both SLEDAI-2K (p<0.001) and 
rSLEDAI (p=0.01) scores were higher in the active group. Serum creatinine (SCr) and eGFR 
values were similar between the 2 groups throughout the study (Table 2). Both ANA (p=0.002) 
and ds-DNA (p=0.002) were significantly higher in the active group at baseline. Complements 
C3 (p<0.001) and C4 (p<0.001) were lower in the active versus the quiescent group at 
baseline, but not at follow-up. Qualitative and quantitative assessment of blood and protein 
in the urine were significantly higher in the active group at baseline compared to the 
quiescent group. Additional laboratory results are shown in Table 2.  
uMCP-1 and uTWEAK Results 
The results for the novel biomarkers MCP-1 and TWEAK are presented as absolute values in 
pg/mL (uMCP-1 and uTWEAK) and as values normalised to uCr concentration in pg/mg Cr 
(MCP-1/Cr and TWEAK/Cr) (Table 2). uMCP-1 (1440 [683–2729] vs 256 [175–477] pg/mL, 
p<0.0001) and uTWEAK (209 [117–312] vs 74 [11–173] pg/mL, p=0.0008) were increased in 
the active group when compared with the quiescent group. At six-month and one-year follow-
up there was no significant difference in the results of these biomarkers between the two 
groups (see Figure 1). When normalised for uCr the difference between the groups at baseline 
persisted (MCP-1/Cr 1093 [577–2014] vs 286 [138–774] pg/mg Cr, p<0.001 and TWEAK/Cr 
159 [89–296] vs 63 [26–160] pg/mg Cr, p=0.02). At follow-up these biomarkers were similar 
between the groups. 
Diagnostic Accuracy in Determining Disease Activity 
The baseline results were then used to generate ROC curves as a method of assessing the 
diagnostic accuracy of the biomarkers in determining the active from the quiescent patients 
using their assigned disease status (group) as the comparator (Figure 2 a–d). The specified 
cut-off demonstrates the optimal combination of sensitivity and specificity for the analyte. 
The area under the curve (AUC) parameter illustrates how well the biomarkers performed in 
distinguishing between active and quiescent patients. At a cut-off of 462 pg/mL for uMCP-1, 
we obtained a sensitivity of 95% and specificity of 73% with an area under the curve (AUC) of 
0.875 (95% CI=0.751–0.952, p<0.001). For MCP-1/Cr, a cut-off of 380 pg/mg Cr provided a 
sensitivity of 90% and specificity of 63% (AUC 0.803, 95% CI=0.667–0.902, p<0.0001). At a cut-
off of 193 pg/mL for uTWEAK, a sensitivity of 60% and specificity of 90% was obtained (AUC 
0.783, 95% CI=0.644–0.887, p<0.0001). For TWEAK/Cr, a cut-off of 71 pg/mg Cr had a 
sensitivity of 85% and specificity of 53% (AUC 0.689, 95% CI=0.0.543–0.812, p=0.013).  
Correlation Throughout Study 
Further analyses were performed using Spearman’s rank test to evaluate the correlation 
between biomarker levels and clinical scores, throughout the study, and is shown in 
Supplementary Table 1. uMCP-1, uTWEAK, MCP-1/Cr and TWEAK/Cr showed significant 
correlation with each other, disease activity scores (SLEDAI-2K, rSLEDAI, SLICC), remission 
status, autoantibodies (ANA and dsDNA), dipsticks haematuria and proteinuria, and UPCR.  
Remission Status 
Supplementary Table 2 and Supplementary Figure 1 show the remission status of the patients. 
At baseline, all participants in the active group were NR. In the quiescent group, 10% were 
NR, 37% were PR and 53% were CR. In the active group at six-months, 11 participants had 
improved, and 2 remained NR. In the quiescent group, 72% remained the same, however 5 
patients had worsened. In the active group at one-year, when compared to their status at 
their previous visit, 3 had improved, 7 remained the same, and 7 had worsened. In the 
quiescent group, 4 had improved, 13 remained the same, and 3 had worsened.       
Table 3 shows a summary of both biomarker levels by remission status. uMCP-1 and MCP/Cr 
results differentiated the three remission status groups from one another (NR, PR and CR), 
whereas uTWEAK and TWEAK/Cr results were able to differentiate NR from PR and CR, but 
not PR from CR.  
Discussion 
Interest in identifying and validating useful biomarkers for LN persists. The main findings of 
our study include: (i) significant differences in both biomarker levels between patients with 
active and quiescent LN, suggesting the usefulness of these biomarkers in disease activity 
monitoring; (ii) both urinary biomarkers correlated with disease activity scores, various 
biochemical tests and with remission status throughout the study; (iii) uMCP-1 and uTWEAK 
performed better than values normalised to creatinine in terms of diagnostic accuracy on ROC 
curve analysis.   
A pathogenic role for MCP-1 in the initiation and progression of LN has been characterised. 
In animal models, MCP-1 antagonism or gene therapy ameliorated these effects and MCP-1 
knockout mice were less prone to LN(18–20). In humans, when compared to a wide range of 
cytokines, uMCP-1 performed better as a marker of disease activity in SLE, was reported to 
correlate with LN disease activity and seemed to have the potential to predict renal 
flares(21,22). In children with SLE, uMCP-1 performed well as a biomarker for LN, was 
increased in active vs inactive LN (or SLE without LN) and SLE vs controls, while correlating 
with SLEDAI scores and biochemical measures of disease status(23). In adults, a meta-analysis 
that included eight studies with 399 patients showed that uMCP-1 was consistently elevated 
in active vs quiescent LN (or control participants)(24). Therefore, uMCP-1 has proven to be a 
biomarker in LN with great potential(21), although further studies are still needed in different 
population groups to demonstrate clinical benefit.  
Activated monocytes and macrophages infiltrate the kidneys in the pathogenesis of LN and 
are a major source of TWEAK(8). TWEAK effects downstream expression of inflammatory 
messengers, including MCP-1, in human mesangial cells, podocytes, and tubular 
cells(8,25).  In early multicentre studies of SLE patients by Schwartz and colleagues, uTWEAK 
higher in those with LN, than in control groups without (overall p=0.039; SLE non-LN p=0.005; 
healthy control p=0.003; rheumatoid arthritis p=0.013). Additionally, they found uTWEAK 
levels would peak during a LN flare, and decrease after the flare, indicating its potential 
usefulness as a marker of LN disease activity(15,26). Similarly, the active group of our study 
had high levels of uTWEAK at baseline, the period in which they were experiencing a renal 
flare, along with increased levels of uMCP-1. More recently, studies in Egypt(27–30), 
China(31,32), Colombia(33), Korea(34), Mexico(35) and Thailand(36) have confirmed 
uTWEAK’s potential as a biomarker in diverse populations of LN. A 2017 meta-analysis that 
included eight of these studies confirmed uTWEAK to be elevated in patients with active LN 
vs quiescent LN (p=0.006)(37).  
Alharazy et al performed a study in a Malaysian LN population in which they assessed uMCP-
1 levels at baseline, two-months and four-months, and found uMCP-1 to be higher in the 
active group and in participants who relapsed. In response to treatment, and especially in 
those who achieved remission, uMCP-1 progressively decreased from baseline until the end 
of the study(38). These trends were mirrored in our study in most indicators of LN disease 
activity, however SLEDAI-2K, remained different between the groups at both follow-ups. At 
one-year, rSLEDAI was again different between the groups and TWEAK/Cr was borderline for 
significance. These findings are compelling in view of the increase in the number of 
participants with a no remission status (9 in the active group at one-year vs only 2 at 6-months 
– Supplementary Table 2). While LN is a disease known to relapse and remit, both biomarkers 
maintained correlation with remission status throughout the study and showed higher 
strength of correlation than many standard measures of disease activity.  
It is uncertain why the TWEAK/Cr results were borderline for significance at one year. An 
explanation could be that the active patients were now on maintenance therapy and 
therefore, less potent treatment regimens, with an overall re-emergence of the underlying 
inflammatory pathways. Urine protein and blood had also increased at one-year, while Hb 
had decreased, in support of this explanation. The UPCR at this time point was, however, not 
different between the two groups.  
Alharazy et al described the remission status of their patients in their longitudinal MCP-1 
study(38). They found a difference in uMCP-1 levels between patients with CR, or PR, when 
compared with NR, or those that relapsed (at baseline p=0.002, two-months p<0.001, four-
months p<0.001). uMCP-1 levels were highest in patients with relapse, followed by no 
remission and lastly CR or PR. In our study, uMCP-1 levels (and MCP-1/Cr) were different in 
the NR, PR and CR groups defined throughout the study. TWEAK levels have also been 
described in terms of remission status and are consistent with our findings. Suttichet et al, in 
a longitudinal multi-centre study, demonstrated that uTWEAK levels were persistently 
elevated in NR, trend down by 3 months in PR, and were consistently low in CR(36). Thus, 
uMCP-1 and TWEAK are able to identify the remission status of patients with LN and may be 
able to identify renal flare (Supplementary Figure 1).  
ROC curve analysis in our study confirmed uMCP-1 to be a good test for determining disease 
activity in LN with an AUC of 0.875 (sensitivity 95%, specificity 73%). When normalized MCP-
1/Cr performed less well than uMCP-1, however it was still above 80% and therefore a good 
test. uTWEAK had a higher specificity (90%) for disease activity as has been shown in a 
previous studies by Dong et al (specificity 93%, sensitivity 62%, AUC 0.81)(32) and Selim et al 
(90% specificity, 77.3% sensitivity, AUC 0.88)(30). This enhanced specificity has not been 
demonstrated in all studies of TWEAK(29,39) and was lost in our study when normalised as 
uTWEAK/Cr (specificity 53%, sensitivity 85%, AUC 0.689). The utility of normalising urine 
results to urine creatinine is discussed below.   
uMCP-1, uTWEAK, MCP-1/Cr and TWEAK/Cr correlated significantly with one another 
throughout the study. With some exceptions, the novel biomarkers demonstrated correlation 
with the results of traditional measures of disease activity status, both positive (SLEDAI-2K, 
rSLEDAI, remission status, ANA, dsDNA, TSB, TSP and UPCR), and negative (C3 and C4). In a 
study by El-shehaby et al, urinary MCP-1 (p<0.001) and TWEAK (p<0.001) levels were 
increased in SLE patients with LN(27). Similar to our study, they found that rSLEDAI scores 
correlated positively with MCP-1 (r=0.635, p<0.001) and TWEAK (r=0.612, p< 0.001). MCP-1 
also correlated with C3 (r=–0.49, p<0.001), and C4 (r=–0.324, p=0.005), while TWEAK 
correlated with haematuria (r=0.254, p=0.03), C3 (r=–0.544, p<0.001) and C4 (r=–0.409, 
p<0.001). In other studies, TWEAK variably correlated with indices of disease activity such as 
SLEDAI, rSLEDAI, proteinuria, haematuria, C3, and C4(27,30,32,37,39).  
Previous studies of uMCP-1 and uTWEAK have reported either absolute concentrations 
(pg/mL) or normalised to creatinine in the urine sample (pg/mg Cr). This calculation is 
traditionally performed to account for differences in hydration status of random urine 
samples, with UPCR being a widely accepted and utilised method of correction. We reported 
both and consider further discussion warranted as the two biomarkers generally performed 
better without normalisation as evidenced by ROC curve analysis. How urinary biomarker 
concentrations should be reported, and whether or not they should be normalised to urinary 
creatinine concentration, is still controversial(40). Implicit assumptions are made. The first 
assumption is that glomerular filtration accounts for the analyte’s appearance in the urine. 
MCP-1 and TWEAK, however, mostly appear in the urine as a result of the local inflammatory 
environment, not filtration. Correcting for creatinine may therefore falsely assess the true 
activity of the inflammatory process occurring renally. Schwartz et al also did not find 
correlation between proteinuria and TWEAK/Cr levels, indicating that increased TWEAK in the 
urine is not reflective of a loss of the glomerular filtration barrier with subsequent overflow 
of protein into the urine(26). The second assumption is that a linear relationship exists for all 
patient results between the appearance of creatinine and the biomarker in the urine. We 
know, however, that patients with active disease processes are not likely to be in steady-
state, whereas quiescent patients are. While normalisation may be useful and valid for the 
evaluation of chronic kidney disease, it may be inappropriate in acute disease states(40,41). 
The third assumption is that assays perform well irrespective of the urine sample’s hydration 
status. The challenges of measuring biomarkers in urine with ELISA methodology have been 
documented(42,43). Although most studies have found urine to be the matrix of choice in LN, 
a study in Korean females with SLE found that the serum level of TWEAK reflected both SLE 
and LN disease activity, whereas the urinary level of TWEAK, and the serum and urinary level 
of MCP-1, did not(34).  In summary, the validity of normalisation of values is probably more 
appropriate in chronic rather than acute kidney conditions, and it is advisable that studies 
report both absolute and normalised values.  
The strengths of the present study include: measurement of two novel urinary biomarkers 
longitudinally over one year, all participants had biopsy-proven LN (with the active arm’s 
biopsy was around the time of enrollment), reporting of both absolute and normalized 
results, and the first study of both biomarkers in a Sub-Saharan population. The weaknesses 
of this study include: due to ethical and other considerations, renal biopsy was not performed 
on the quiescent group to exclude disease activity at enrollment, and there was a decrease in 
sample number at follow-up (especially in quiescent group). 
uMCP-1 and uTWEAK reflect LN disease activity, and correlate with other standard of care 
biomarkers in a South African cohort, however, further studies are needed to assess 
additional clinical benefit. Nevertheless, the usefulness of these biomarkers may be enhanced 
by incorporating several biochemical markers into a panel for assessing LN disease activity.     
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Tables and Figures 





n = 50 
Active 
n = 20 
Quiescent 
n = 30 
Demographics 
   
- Age (years) 36 (27–41) **26 (23–40) 36 (30–41) 
- Weight (kg) 65 (58–73) 60 (56–66) 68 (60–78) 
- Female (n [%]) 38 (76) 14 (70) 24 (80) 
Ethnicity (n [%]) 
   
- Black 16 (32) 7 (35) 9 (30) 
- Mixed Ancestry 32 (64) 12 (60) 20 (67) 
- Indian 1 (2) 0 (0) 1 (3) 
- White 1 (2) 1 (5) 0 (0) 
Duration of SLE (years) 8 (3–12) *2 (1–7) 10 (8–15) 
Biopsy features (%) 
   
- Class II  10  
- Class III  15  
- Class IV  45  
- Class III + V  5  
- Class IV + V 
- Class V  
5 
20  
- Activity index  4 (2–9)  
- Chronicity index  2 (1–4)  
    
Results expressed as median (M) and interquartile ranges (IQR)- M(25–75). n - sample number; kg – 
kilogram. Class II – mesangial proliferative lupus glomerulonephritis (LGN); Class III – focal LGN; Class 
IV – diffuse segmental or global LGN; Class V – Membranous LGN. Proliferative LN includes classes III, 
IV, III+V and IV+V; Non-proliferative LN includes classes I, II and V). Asterisks demonstrate significant 
difference between active and quiescent groups: * p<0.001; ** p<0.05 
Table 2: Laboratory Results and Clinical Scores at Baseline, Six-Months and One-Year 
  BASELINE   SIX-MONTHS   ONE-YEAR   
VARIABLE Active Quiescent Active Quiescent Active Quiescent 
Number n = 20 n = 30 n = 14 n = 18 n = 17 n = 19 
SLEDAI-2K *17 (13–27) 0 (0–0) ***4 (0–12) 0 (0–0) *8 (4–10) 0 (0–2) 
rSLEDAI *8 (8–12) 0 (0–4) 4 (0–4) 4 (0–4) **4 (0–8) 0 (0–0) 
SLICC *1.5 (1–2) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–0) 
Blood       
Creatinine (umol/L) 104 (57–154) 76 (57–95) 91 (56–130) 74 (56–100) 76 (60–134) 81 (66–102) 
eGFR (ml/min/1.73m2) 64 (41–117) 96 (64–119) 91 (53–113) 102 (67–122) 81 (51–117) 82 (68–107) 
ANA *32 (22–40) 9.7 (0.9–26)     
ds-DNA (IU/mL) ***248 (66.5–379) 28.5 (4.8–86) 23 (12–109) 42 (3.4–90) 12 (8.6–61) 36 (5.1–75) 
Anti-Sm (U/mL) 3.3 (0.9–75.7) 1.2 (0.7–3.4) 1.6 (0.7–9.5) 1.1 (0.8–2.3) 2.4 (0.6–72.9) 1.0 (0.6–2.9) 
C3 (g/L) *0.4 (±0.2) 0.9 (±0.2) 1.0 (±0.3) 1.0 (±0.3) 1.0 (±0.4) 1.1 (±0.3) 
C4 (g/L) *0.09 (0.04–0.14) 0.22 (0.16–0.25) 0.21 (0.14–0.23) 0.29 (0.24–0.32) 0.20 (0.15–0.31) 0.23 (0.18–0.33) 
Hb (g/dL)  *9.2 (8.1–10)  12.1 (10.9–13)  11.4 (11–12.1)  11.8 (10.4–13.4)  11.1 (10.2–12.3)  #12.3 (11.2–12.8) 
WBC (x10^9/L)  5.9 (4.0–8.9) 6.0 (5.0–6.3) 7.4 (5.2–10.3) 5.2 (4.7–6.2) 4.5 (3.4–7.0) 5.4 (3.0–13.7) 
Platelets (x10^9/L)  240 (±136) 295 (±109) 264 (±83) 264 (±68) 286 (±115) 268 (±65) 
Urine       
TSP *3 (2–3) 1 (0–1) 2 (0–2) 0 (0–1) **2 (1–2) 0 (0–1) 
TSB *3 (1–3) 0 (0–0) 0 (0–0) 0 (0–0) ***0 (0–2) 0 (0–0) 












Creatinine (mmol/L) 12.2 (±7.8) 10.0 (±5.7) 12.7 (±11.3) 12.6 (±4.9) 13.7 (±6.1) 14.8 (±8.1) 
MCP-1 (pg/mL) *1440 (683–2729) 256 (175–477) 484 (217–830) 297 (131–686) 421 (203–1004) 363 (183–657) 
MCP-1/Cr (pg/mgCr) *1093 (577–2014) 286 (138–774) 328 (241–648) 205 (115–397) 332 (211–484) 211 (105–473) 
TWEAK (pg/mL) *209 (117–312) 74 (11–173) 42 (21–70) 27 (8–35) 65 (28–164) 40 (17–78) 
TWEAK/Cr (pg/mgCr) **159 (89–296) 63 (26–160) 43 (15–106) 18 (6–32) #53 (25–106) 22 (13–67) 
Results expressed as M(25–75]) for non-parametric data or mean (C) and standard deviation C (±SD) - for parametric data. eGFR – estimated glomerular filtration rate; TSP – test strip protein; TSB – test strip 
blood. A significant difference between the active and quiescent group is demonstrated in bold and symbols demonstrate the level of significance as follows: * p<0.001; ** p<0.05; *** p<0.01; # p=0.05   
 
 
Figure 1: Longitudinal analysis of MCP-1 and TWEAK Concentrations 
Box and whisker plots of MCP-1, MCP-1/Cr, Tweak and TWEAK/Cr at baseline, six-months and one-year. 
The inactive group is represented in bold on the left and the active group on the right (dashed line). 




Figure 2 (a-d): Diagnostic Accuracy in Identifying Disease Activity 
Receiver Operating Characteristic (ROC) Curves for the biomarkers MCP-1 and TWEAK, and normalised 
to urinary creatinine MCP-1/Cr and TWEAK/Cr, using results generated at baseline with activity status as 





Supplementary Table 1: Spearman’s Rank Correlations Between Biomarkers with rho (r) and p-values (p) 
    uMCP1 uTWEAK MCP1/Cr TWEAK/Cr SLEDAI rSLEDAI SLICC RemStat ANA dsDNA C3 C4 eGFR Hb TSB TSP UPCR 
uMCP1 r   0.52 0.86 0.31 0.48 0.43 0.23 0.57 0.43 0.35 -0.37 -0.30 -0.25 -0.47 0.39 0.51 0.44 
  p   <0.001 <0.001 <0.001 <0.001 <0.001 0.01 <0.001 0.004 <0.001 <0.001 0.005 0.007 <0.001 <0.001 <0.001 <0.001 
uTWEAK r 0.52   0.51 0.88 0.41 0.39 0.33 0.46 0.53 0.32 -0.29 -0.27 -0.17 -0.41 0.40 0.51 0.38 
  p <0.001   <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.005 0.009 0.07 <0.001 <0.001 <0.001 <0.001 
MCP1/Cr r 0.86 0.51   0.51 0.45 0.48 0.30 0.60 0.41 0.40 -0.33 -0.28 -0.22 -0.51 0.36 0.49 0.44 
  p <0.001 <0.001   <0.001 <0.001 <0.001 0.001 <0.001 0.006 <0.001 0.001 0.009 0.01 <0.001 <0.001 <0.001 <0.001 
TWEAK/Cr r 0.31 0.88 0.51   0.33 0.37 0.34 0.40 0.41 0.31 -0.23 -0.18 -0.09 -0.38 0.34 0.41 0.33 
  p <0.001 <0.001 <0.001   <0.001 <0.001 <0.001 <0.001 0.006 <0.001 0.02 0.09 0.33 <0.001 <0.001 <0.001 <0.001 
SLEDAI r 0.48 0.41 0.45 0.33   0.68 0.35 0.59 0.57 0.35 -0.48 -0.49 -0.16 -0.32 0.57 0.63 0.49 
  p <0.001 <0.001 <0.001 <0.001   <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.08 <0.001 <0.001 <0.001 <0.001 
rSLEDAI r 0.43 0.39 0.48 0.37 0.68   0.44 0.77 0.34 0.25 -0.29 -0.37 -0.26 -0.28 0.72 0.69 0.72 
  p <0.001 <0.001 <0.001 <0.001 <0.001   <0.001 <0.001 0.02 0.006 0.005 <0.001 0.004 0.002 <0.001 <0.001 <0.001 
SLICC r 0.23 0.33 0.30 0.34 0.35 0.44   0.39 0.27 0.21 -0.32 -0.16 -0.32 -0.32 0.42 0.32 0.36 
  p 0.02 <0.001 0.001 <0.001 <0.001 <0.001   <0.001 0.08 0.03 0.003 0.1 <0.001 0.001 <0.001 <0.001 <0.001 
RemStat r 0.57 0.46 0.60 0.40 0.59 0.77 0.39   0.39 0.27 -0.35 -0.28 -0.31 -0.40 0.46 0.80 0.85 
  p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001   0.009 0.003 <0.001 0.008 <0.001 <0.001 <0.001 <0.001 <0.001 
ANA r 0.43 0.53 0.41 0.41 0.57 0.34 0.27 0.39   0.63 -0.69 -0.62 -0.13 -0.52 0.40 0.35 0.21 
  p 0.004 <0.001 0.006 0.006 <0.001 0.02 0.08 0.009   <0.001 <0.001 <0.001 0.40 <0.001 0.006 0.02 0.1 
dsDNA r 0.35 0.32 0.40 0.31 0.35 0.25 0.21 0.27 0.63   -0.72 -0.61 -0.02 -0.31 0.36 0.25 0.19 
  p <0.001 <0.001 <0.001 <0.001 <0.001 0.006 0.03 0.003 <0.001   <0.001 <0.001 0.8 <0.001 <0.001 0.007 0.04 
C3 r -0.37 -0.29 -0.33 -0.23 -0.48 -0.29 -0.32 -0.35 -0.69 -0.72   0.65 0.16 0.36 -0.39 -0.23 -0.23 
  p <0.001 0.005 0.001 0.02 <0.001 0.005 0.003 <0.001 <0.001 <0.001   <0.001 0.1 <0.001 <0.001 0.03 0.03 
C4 r -0.30 -0.27 -0.28 -0.18 -0.49 -0.37 -0.16 -0.28 -0.62 -0.61 0.65   -0.03 0.21 -0.32 -0.26 -0.31 
  p 0.005 0.009 0.009 0.09 <0.001 <0.001 0.1 0.008 <0.001 <0.001 <0.001   0.7 0.049 0.002 0.01 0.003 
eGFR r -0.25 -0.17 -0.22 -0.09 -0.16 -0.26 -0.32 -0.31 -0.13 -0.02 0.16 -0.03   0.27 -0.23 -0.17 -0.00 
  p 0.007 0.07 0.01 0.33 0.08 0.004 <0.001 <0.001 0.40 0.8 0.1 0.7   0.002 0.01 0.06 0.9 
Hb r -0.47 -0.41 -0.51 -0.38 -0.32 -0.28 -0.32 -0.40 -0.52 -0.31 0.36 0.21 0.27   -0.27 -0.27 -0.23 
  p <0.001 <0.001 <0.001 <0.001 <0.001 0.002 0.001 <0.001 <0.001 <0.001 <0.001 0.049 0.002   0.003 0.003 0.01 
TSB r 0.39 0.40 0.36 0.34 0.57 0.72 0.42 0.46 0.40 0.36 -0.39 -0.32 -0.23 -0.27   0.47 0.36 
  p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.006 <0.001 <0.001 0.002 0.01 0.003   <0.001 <0.001 
TSP r 0.51 0.51 0.49 0.41 0.63 0.69 0.32 0.80 0.35 0.25 -0.23 -0.26 -0.17 -0.27 0.47   0.76 
  p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.02 0.007 0.03 0.01 0.06 0.003 <0.001   <0.001 
UPCR r 0.44 0.38 0.44 0.33 0.49 0.72 0.36 0.85 0.21 0.19 -0.23 -0.31 -0.00 -0.23 0.36 0.76   
  p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.1 0.043 0.03 0.003 0.9 0.01 <0.001 <0.001   
Spearman’s rank correlation with rho (r) and p-value for significance (p). Significant results are highlighted in black; 
non-significant results are grey. Rho values can be categorises as follows: 0.0-0.19 “very weak”, 0.20-0.39 “weak”, 






















Supplementary Table 2: Remission Status at Baseline and Follow-up 
    Active Quiescent 
Baseline  n=20  n=30 
 
NR 20(100) 3(10) 
 
PR 0(0) 11(37) 
 
CR 0(0) 16(53) 
6-Months n=13 n=18 
  NR 2(15) 4(22) 
 
PR 6(46) 7(39) 
 
CR 5(38) 7(39) 
 
Improved 11(85) 0(0) 
 
Same  2(15) 13(72) 
 
Worsened 0(0) 5(28) 
1-Year n=17  n=20  
  NR 9(53) 6(30) 
 
PR 5(29) 2(10) 
 
CR 3(18) 12(60) 
 
Improved 3(18) 4(20) 
 
Same  7(41) 13(65) 
  Worsened 7(41) 3(15) 
Remission status (no remission [NR], partial remission [PR] and complete remission [CR]) is shown here for the active 
and quiescent groups as number (percentage) in the group. Whether the patients had improved, stayed the same or 





Supplementary Figure 1: Biomarker Concentrations as a Function of Remission 
Status 
Box and whisker plots demonstrating the concentrations of MCP-1, MCP/Cr, TWEAK and 
TWEAK/Cr when plotted according to complete remission (CR), partial remission (PR) and 
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Table 3: Remission Status 
 
    Remission Status   
    None Partial Complete 
uMCP-1   1020 (530-1951) 387 (203-606) 230 (113-433) 
 
Partial p<0.001     
 
Complete p<0.001 p=0.04   
uTWEAK   145 (70-221) 32 (23-53) 28 (8-89) 
 
Partial p<0.001     
 
Complete p<0.001 p=0.6   
MCP/Cr   795 (426 -1496) 310 (203-505) 139 (94-301) 
 
Partial p<0.001     
 
Complete p<0.001 <0.001   
TWEAK/Cr   102 (58-183) 27 (17-58) 27 (8-88) 
 
Partial p<0.001     
  Complete p<0.001 p=0.5   
 
Biomarker results according to no, partial or complete remission status (see text for definitions). The 
Mann-Whitney test was used to compare the biomarker values for each remission status group (with 
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Manuscript Submission Guidelines: Lupus 
This Journal is a member of the Committee on Publication Ethics. 
This Journal recommends that authors follow the Recommendations for the Conduct, 
Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the 
International Committee of Medical Journal Editors (ICMJE). 
Only manuscripts of sufficient quality that meet the aims and scope of Lupus will be 
reviewed. 
There are no fees payable to submit or publish in this journal. 
As part of the submission process you will be required to warrant that you are submitting 
your original work, that you have the rights in the work, that you are submitting the work 
for first publication in the Journal and that it is not being considered for publication 
elsewhere and has not already been published elsewhere, and that you have obtained and 
can supply all necessary permissions for the reproduction of any copyright works not owned 
by you. 
1. What do we publish?
1.1 Aims & Scope 
The only fully peer-reviewed international journal devoted exclusively to lupus (and related 
disease) research.  
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Lupus includes the most promising new clinical and laboratory-based studies from leading 
specialists in all lupus-related disciplines. 







Leading international specialists present their findings on Lupus, in one outstanding 
reference.  
1.2 Article Types 
Lupus is published fourteen times a year. The Editor will consider for publication all suitable 
papers dealing directly or indirectly with lupus or related diseases. The journal publishes 
both clinical and non-clinical research papers. Original research articles should be limited to 
no more than 4,000 words, 50 references and 6 tables and/or figures. They will be peer 
reviewed by two referees. In addition to original papers, the journal also publishes 
editorials, reports, and letters. 
EDITORIALS 
Editorials are solicited by the Editor but suggestions for such material will be very welcome. 
GRAND ROUNDS CASES 
The purpose of a grand rounds submission is to educate the reader about one or more 
facets related to the disease lupus or of an autoimmune disease which is related to lupus. A 
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clinicopathological conference can be submitted but this must have postmortem data and is 
usually a death conference or mortality conference. 
Avoid extraneous material which has little bearing on the case at hand. The readers wish to 
learn about every facet of the case presented and not about other unrelated material. 
The submitted case should contain: 
Introduction - This should be no more than one or two short paragraphs and summarise 
what is about to be presented and the reasons why the case was chosen. 
Case Presentation - This part contains a succinct narrative of the case itself. Figures, 
photographs and tables with data are welcome. Also encouraged are data on biopsies with 
illustrative materials if possible. 
Discussion - The discussion should be a focused presentation of theory and/or pathogenetic 
data regarding the case. 
Final Diagnosis - This should be only one sentence which gives the final diagnosis. 
CONCISE REPORTS 
These should be short investigative papers and reports organised in the same way as full-
length manuscripts but which contain 2000 words or less, with no more than 3 figures or 
tables and up to 15 references. 
CASE REPORTS 
The Editor will consider for publication case reports that illustrate points not previously 
reported in the literature. They should not exceed two printed pages in length. The number 
of references should not exceed ten. 
The number of case reports published in Lupus will be strictly limited. 
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LETTERS TO THE EDITOR 
Letters to the Editor are encouraged. They may deal with material in published papers or 
they may raise new issues. Short clinical or laboratory observations may also be presented 
as Letters. 
Letters must contain no more than 500 words, 10 references, 1 table and/or 1 illustration. 
An abstract is not required and letters should not be divided into sections. Instructions for 
references, tables and figures are the same as for full length articles. 
SUPPLEMENTS 
The journal welcomes the opportunity of publishing supplements to regular issues of 
significant symposia providing the material represents original work not previously 
published. 
Sponsored symposia should be fully discussed with the Editor prior to agreement to publish. 
Faculty, subject matter and editorial content are all subject to the approval of the editorial 
office and the journal's integrity and reputation should in no way be compromised. 
1.3 Writing your paper 
The SAGE Author Gateway has some general advice and on how to get published, plus links 
to further resources. 
1.3.1 Make your article discoverable 
When writing up your paper, think about how you can make it discoverable. The title, 
keywords and abstract are key to ensuring readers find your article through search engines 
such as Google. For information and guidance on how best to title your article, write your 
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abstract and select your keywords, have a look at this page on the Gateway: How to Help 
Readers Find Your Article Online. 
2. Editorial policies 
2.1 Peer review policy 
The journal's policy is to obtain at least two independent reviews of each article. Lupus 
operates a conventional single-blind reviewing policy in which the reviewer's name is always 
concealed from the submitting author.  Referees will be encouraged to provide substantive, 
constructive reviews that provide suggestions for improving the work and distinguish 
between mandatory and non-mandatory recommendations.  All manuscripts accepted for 
publication are subject to editing for presentation, style and grammar. Any major redrafting 
is agreed with the author but the Editor's decision on the text is final. 
As part of the submission process you will be asked to provide the names of peers who 
could be called upon to review your manuscript. Recommended reviewers should be 
experts in their fields and should be able to provide an objective assessment of the 
manuscript. Please be aware of any conflicts of interest when recommending reviewers. 
Examples of conflicts of interest include (but are not limited to) the below:  
• The reviewer should have no prior knowledge of your submission 
• The reviewer should not have recently collaborated with any of the authors 
• Reviewer nominees from the same institution as any of the authors are not 
permitted 
Please note that the Editors are not obliged to invite any recommended/opposed reviewers 
to assess your manuscript. 
2.2 Authorship 
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Papers should only be submitted for consideration once consent is given by all contributing 
authors. Those submitting papers should carefully check that all those whose work 
contributed to the paper are acknowledged as contributing authors. 
The list of authors should include all those who can legitimately claim authorship. This is all 
those who: 
1. Made a substantial contribution to the concept or design of the work; or acquisition, 
analysis or interpretation of data, 
2. Drafted the article or revised it critically for important intellectual content, 
3. Approved the version to be published, 
4. Each author should have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content. 
Authors should meet the conditions of all of the points above. When a large, multicentre 
group has conducted the work, the group should identify the individuals who accept direct 
responsibility for the manuscript. These individuals should fully meet the criteria for 
authorship. 
Acquisition of funding, collection of data, or general supervision of the research group alone 
does not constitute authorship, although all contributors who do not meet the criteria for 
authorship should be listed in the Acknowledgments section. Please refer to the 
International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more 
information on authorship. 
2.3 Acknowledgements 
All contributors who do not meet the criteria for authorship should be listed in an 
Acknowledgements section. Examples of those who might be acknowledged include a 
Page | 28  
 
person who provided purely technical help, or a department chair who provided only 
general support. 
2.3.1 Writing assistance 
Individuals who provided writing assistance, e.g. from a specialist communications 
company, do not qualify as authors and so should be included in the Acknowledgements 
section. Authors must disclose any writing assistance – including the individual’s name, 
company and level of input – and identify the entity that paid for this assistance”). 
It is not necessary to disclose use of language polishing services. 
Any acknowledgements should appear first at the end of your article prior to your 
Declaration of Conflicting Interests (if applicable), any notes and your References. 
2.4 Funding 
Lupus requires all authors to acknowledge their funding in a consistent fashion under a 
separate heading.  Please visit the Funding Acknowledgements page on the SAGE Journal 
Author Gateway to confirm the format of the acknowledgment text in the event of funding, 
or state that: This research received no specific grant from any funding agency in the public, 
commercial, or not-for-profit sectors.  
2.5 Declaration of conflicting interests 
It is the policy of Lupus to require a declaration of conflicting interests from all authors 
enabling a statement to be carried within the paginated pages of all published articles. 
Page | 29  
 
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of 
your manuscript, after any acknowledgements and prior to the references. If no conflict 
exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.  
2.6 Research ethics and patient consent 
Medical research involving human subjects must be conducted according to the World 
Medical Association Declaration of Helsinki. 
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, 
Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers 
reporting animal and/or human studies must state in the methods section that the relevant 
Ethics Committee or Institutional Review Board provided (or waived) approval. Please 
ensure that you have provided the full name and institution of the review committee, in 
addition to the approval number. 
For research articles, authors are also required to state in the methods section whether 
participants provided informed consent and whether the consent was written or verbal. 
Information on informed consent to report individual cases or case series should be 
included in the manuscript text. A statement is required regarding whether written 
informed consent for patient information and images to be published was provided by the 
patient(s) or a legally authorized representative. 
Please also refer to the ICMJE Recommendations for the Protection of Research 
Participants. 
All research involving animals submitted for publication must be approved by an ethics 
committee with oversight of the facility in which the studies were conducted. The journal 
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has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary 
Journals published by the International Association of Veterinary Editors 
2.7 Clinical trials 
Lupus conforms to the ICMJE requirement that clinical trials are registered in a WHO-
approved public trials registry at or before the time of first patient enrolment as a condition 
of consideration for publication. The trial registry name and URL, and registration number 
must be included at the end of the abstract. 
2.8 Reporting guidelines 
The relevant EQUATOR Network reporting guidelines should be followed depending on the 
type of study. For example, all randomized controlled trials submitted for publication should 
include a completed CONSORT flow chart as a cited figure and the completed CONSORT 
checklist should be uploaded with your submission as a supplementary file. Systematic 
reviews and meta-analyses should include the completed PRISMA flow chart as a cited 
figure and the completed PRISMA checklist should be uploaded with your submission as a 
supplementary file. The EQUATOR wizard can help you identify the appropriate guideline. 
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives. 
2.9 Data 
SAGE acknowledges the importance of research data availability as an integral part of the 
research and verification process for academic journal articles. 
Lupus requests all authors submitting any primary data used in their research articles 
[alongside their article submissions to be published in the online version of the journal, or 
provide detailed information in their articles on how the data can be obtained. This 
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information should include links to third-party data repositories or detailed contact 
information for third-party data sources. Data available only on an author-maintained 
website will need to be loaded onto either the journal’s platform or a third-party platform 
to ensure continuing accessibility. Examples of data types include but are not limited to 
statistical data files, replication code, text files, audio files, images, videos, appendices, and 
additional charts and graphs necessary to understand the original research. The editor(s) 
may consider limited embargoes on proprietary data. The editor(s) can also grant exceptions 
for data that cannot legally or ethically be released. All data submitted should comply with 
Institutional or Ethical Review Board requirements and applicable government regulations. 
For further information, please contact the editorial office at editorial@Lupusjournal.co.uk  
3. Publishing Policies 
3.1 Publication ethics 
SAGE is committed to upholding the integrity of the academic record. We encourage 
authors to refer to the Committee on Publication Ethics’ International Standards for 
Authors and view the Publication Ethics page on the SAGE Author Gateway. 
3.1.1 Plagiarism 
Lupus and SAGE take issues of copyright infringement, plagiarism or other breaches of best 
practice in publication very seriously. We seek to protect the rights of our authors and we 
always investigate claims of plagiarism or misuse of published articles. Equally, we seek to 
protect the reputation of the journal against malpractice. Submitted articles may be 
checked with duplication-checking software. Where an article, for example, is found to have 
plagiarised other work or included third-party copyright material without permission or with 
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insufficient acknowledgement, or where the authorship of the article is contested, we 
reserve the right to take action including, but not limited to: publishing an erratum or 
corrigendum (correction); retracting the article; taking up the matter with the head of 
department or dean of the author's institution and/or relevant academic bodies or societies; 
or taking appropriate legal action. 
3.1.2 Prior publication 
If material has been previously published it is not generally acceptable for publication in a 
SAGE journal. However, there are certain circumstances where previously published 
material can be considered for publication. Please refer to the guidance on the SAGE Author 
Gateway or if in doubt, contact the Editor at the address given below. 
3.2 Contributor's publishing agreement 
Before publication, SAGE requires the author as the rights holder to sign a Journal 
Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is 
an exclusive licence agreement which means that the author retains copyright in the work 
but grants SAGE the sole and exclusive right and licence to publish for the full legal term of 
copyright. Exceptions may exist where an assignment of copyright is required or preferred 
by a proprietor other than SAGE. In this case copyright in the work will be assigned from the 
author to the society. For more information please visit the SAGE Author Gateway. 
3.3 Open access and author archiving 
Lupus offers optional open access publishing via the SAGE Choice programme. For more 
information please visit the SAGE Choice website. For information on funding body 
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compliance, and depositing your article in repositories, please visit SAGE Publishing 
Policies on our Journal Author Gateway. 
4. Preparing your manuscript for submission 
Authors are asked to write their manuscripts in English. Spelling and phraseology should 
conform either to standard UK English or to standard American English and should be 
consistent throughout the paper. 
The Summary should not exceed 200 words. It should be written in a style that conveys the 
essential message of the paper in abbreviated form. 
The Introduction should assume that the reader is knowledgeable in the field and should 
therefore be as brief as possible. 
In the Materials and methods section, methods that have been published in detail 
elsewhere should not be described in detail. SI units should be used throughout the text. 
Tables and figures should be placed after references and not embedded within the text. 
4.1 Formatting 
The preferred format for your manuscript is Word. The text should be double-spaced 
throughout and with a minimum of 3cm for left and right hand margins and 5cm at head 
and foot. Text should be standard 10 or 12 point. LaTeX files are also accepted. Word and 
(La)Tex templates are available on the Manuscript Submission Guidelines page of our 
Author Gateway. 
4.2 Artwork, figures and other graphics 
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For guidance on the preparation of illustrations, pictures and graphs in electronic format, 
please visit SAGE’s Manuscript Submission Guidelines.   
Figures supplied in colour will appear in colour online regardless of whether or not these 
illustrations are reproduced in colour in the printed version. For specifically requested 
colour reproduction in print, you will receive information regarding the costs from SAGE 
after receipt of your accepted article. 
Tables 
Each table should be numbered consecutively with an Arabic numeral. Each should have a 
separate caption or title. Methods not described in the text and abbreviations should be 
explained at the foot of the table. Footnotes should be designated by superior lower case 
letters (a, b, c etc). Vertical lines should not be inserted in the table. Tables must be referred 
to specifically in the text of the paper. 
Figures 
Lettering should be planned for 50% reduction; text should be readable after reduction. 
Figures should be referred to as Figure 1, Figure 2 etc. Figures must be referred to 
specifically in the text of the paper. 
Images should be supplied as bitmap based files (i.e. with .tiff or .jpeg extension) with a 
resolution of at least 300 dpi (dots per inch). Line art should be supplied as vector-based, 
separate .eps files (not as .tiff files, and not only inserted in the Word or pdf file), with a 
resolution of 600 dpi. Images should be clear, in focus, free of pixilation and not too light or 
dark. 
Colour photographs and Figures - Important information 
Colour photographs and Figures, when accepted, will be published online. In the printed 
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version, they will be in black and white (unless colour prints are paid for). Authors who 
submit in colour must ensure that their figures are of the highest definition for the black and 
white version otherwise these may not be accepted. In particular dermatological, immuno-
fluorescent and histological figures must be paid for in colour or omitted from the 
manuscript and replaced in a descriptive format. If, together with your accepted article, you 
submit usable colour figures, these figures will appear in colour online regardless of whether 
or not these illustrations are reproduced in colour in the printed version. For specifically 
requested colour reproduction in print, you will receive information regarding the possible 
costs from SAGE after receipt of your accepted article. 
The colour printing price is £50 for the first figure and £25 for each figure thereafter. 
4.3 Supplementary material 
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, 
images etc) alongside the full-text of the article. For more information please refer to 
our guidelines on submitting supplementary files. 
4.4 Reference style 
Lupus adheres to the SAGE Vancouver reference style. View the SAGE Vancouver guidelines 
to ensure your manuscript conforms to this reference style. 
It is important that references comply with the style of the journal. Exhaustive lists should 
be avoided. References should follow the Vancouver format, listed (double-spaced) in 
numerical order corresponding to the order of citation in the text. 
All authors should be quoted for papers with up to six authors; for papers with more than 
six authors, the first three only should be quoted followed by et al. 
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No issue numbers should be quoted. 
Abbreviations for titles of medical periodicals should conform to those used in the latest 
editions of Index Medicus and Current Contents. The first and last page numbers for each 
reference should be provided. Abstracts and letters must be identified as such. 
Papers in press and papers already submitted for publication may be included in the list of 
references. No citation is required for work that is not yet submitted for publication. 
Personal communications may be allocated a number and included in the list of references 
in the usual way or simply referred to in the text. Authors must obtain permission from the 
individual concerned to quote his or her unpublished work. 
Examples of References: 
Journal article: 
1 Derksen RHWM, Bouma BN, Kater L. The association between the Lupus anticoagulant and 
cerebral infarction in systemic Lupus erythematosus. Scand J Rheumatol 1986; 15: 179-184. 
Journal article, in press: 
2 Mendonca LLF, Khamashta MA, Nelson-Piercy A, Hunt BJ, Hughes GRV. Nonsteroidal anti-
inflammatory drugs as a possible cause for reversible infertility. Rheumatology (in press). 
Journal article submitted for publication: 
3 Khamashta MA, Cervera R, Asherson RA. Association of antibodies against phospholipids 
with heart valve disease in systemic Lupus erythematosus (submitted for publication). 
Complete book: 
4 Wallace DJ, Dubois EL. Dubois' Lupus Erythematosus. Lea & Febiger, 1987, p 51. 
Chapter in book: 
5 Christian CL. Etiologic hypotheses for systemic Lupus erythematosus. In: Lahita RG (ed) 
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Systemic Lupus Erythematosus. Wiley, 1987, 65-79. 
Abstract: 
6 Valesini G, Luan FL, Falco M. Clonal analysis of affinity purified anticardiolipin antibodies. 
Clin Exp Rheumatol 1988; 6: 214 (abstract 102). 
Letter to the Editor: 
7 Sills EM. Systemic Lupus erythematosus in a patient diagnosed as having Shulman disease. 
Arthritis Rheum 1988; 31: 694 (letter). 
4.5 English language editing services 
Authors seeking assistance with English language editing, translation, or figure and 
manuscript formatting to fit the journal’s specifications should consider using SAGE 
Language Services. Visit SAGE Language Services on our Journal Author Gateway for further 
information. 
5. Submitting your manuscript 
Lupus is hosted on SAGE Track, a web based online submission and peer review system 
powered by ScholarOne™ Manuscripts. Visit http://mc.manuscriptcentral.com/Lupus to 
login and submit your article online. 
If you would like to discuss your paper prior to submission contact the Editor:  
Prof. Hughes, editorial@Lupusjournal.co.uk 
5.1 ORCID 
As part of our commitment to ensuring an ethical, transparent and fair peer review process 
SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID 
provides a unique and persistent digital identifier that distinguishes researchers from every 
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other researcher, even those who share the same name, and, through integration in key 
research workflows such as manuscript and grant submission, supports automated linkages 
between researchers and their professional activities, ensuring that their work is 
recognized.  
The collection of ORCID iDs from corresponding authors is now part of the submission 
process of this journal. If you already have an ORCID iD you will be asked to associate that to 
your submission during the online submission process. We also strongly encourage all co-
authors to link their ORCID ID to their accounts in our online peer review platforms. It takes 
seconds to do: click the link when prompted, sign into your ORCID account and our systems 
are automatically updated. Your ORCID iD will become part of your accepted publication’s 
metadata, making your work attributable to you and only you. Your ORCID iD is published 
with your article so that fellow researchers reading your work can link to your ORCID profile 
and from there link to your other publications. 
  
5.2 Information required for completing your submission 
You will be asked to provide contact details and academic affiliations for all co-authors via 
the submission system and identify who is to be the corresponding author. These details 
must match what appears on your manuscript. At this stage please ensure you have 
included all the required statements and declarations and uploaded any additional 
supplementary files (including reporting guidelines where relevant). 
5.3 Permissions 
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Please also ensure that you have obtained any necessary permission from copyright 
holders for reproducing any illustrations, tables, figures or lengthy quotations previously 
published elsewhere. For further information including guidance on fair dealing for criticism 
and review, please see the Copyright and Permissions page on the SAGE Author Gateway. 
6. On acceptance and publication 
6.1 SAGE Production 
Your SAGE Production Editor will keep you informed as to your article’s progress throughout 
the production process. Proofs will be sent by PDF to the corresponding author and should 
be returned promptly.  Authors are reminded to check their proofs carefully to confirm that 
all author information, including names, affiliations, sequence and contact details are 
correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please 
note that if there are any changes to the author list at this stage all authors will be required 
to complete and sign a form authorising the change. 
6.2 Online First publication 
Online First allows final articles (completed and approved articles awaiting assignment to a 
future issue) to be published online prior to their inclusion in a journal issue, which 
significantly reduces the lead time between submission and publication.  
6.3 Access to your published article 
SAGE provides authors with online access to their final article. 
6.4 Promoting your article 
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Publication is not the end of the process! You can help disseminate your paper and ensure it 
is as widely read and cited as possible. The SAGE Author Gateway has numerous resources 
to help you promote your work. Visit the Promote Your Article page on the Gateway for tips 
and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to 
explain, enrich, share, and measure the impact of their article. Find out how to maximise 
your article’s impact with Kudos.  
7. Further information 
Any correspondence, queries or additional requests for information on the manuscript 
submission process should be sent to the Lupus editorial office as follows: 
Prof. GRV Hughes 
editorial@Lupusjournal.co.uk  
Managing Editor: Dr Maria Laura Bertolaccini 
Editorial Assistant: Mrs Den Fletcher 
 
 
 
 
 
 
 
